Esophageal cancer is the seventh most common cancer globally, accounting for more than
half a million of deaths per year. The two most common histologies are adenocarcinoma and
squamous cell carcinoma. Neoadjuvant chemoradiatation therapy followed by surgical
resection has become the mainstay treatment for resectable esophageal cancer. With the
advent of immunotherapy, human monoclonal anti-programmed death (PD-1) antibody has
proven to play a critical role for those who had residual disease following resection.

Dr. Quyen D. Chu is Chair of Surgical Oncology at Orlando Health Cancer Institute.

He earned his bachelor's degree from Dartmouth College and his medical degree at the Brown University School of Medicine. He completed his residency in general surgery at St. Elizabeth’s Medical Center in Boston.

He completed a clinical fellowship in surgical oncology at Roswell Park Cancer Institute in
Buffalo He also earned his Executive MBA at Centenary College, Shreveport, La.